We obtain licensed innovative molecules from pharmaceutical and biotechnology companies and develop them for patients in China, South Korea and beyond.
Our first program is FTC001 which is IL-17A mAb licensed from Janssen Biotech Inc. for  China, Taiwan and South Korea.This asset is ready for Phase1/2 studies in psoriasis. Psoriasis (PsO) has a global prevalence of ~2%, but varies widely depending on genetic background. Caucasian and Scandinavian populations see rates up to 11%. (J. Investig. Dermatol. 2013, 133, 377–385.)
·China is 0.11- 0.47% (Ran Pan, Jianzhong Zhang 2014)
·Korea 0.45% (Jin Yong Lee et al 2017)
·Taiwan 0.24% (Hsien-Yi Chiu et al 2018)
·China is 0.3% ~ 0.5%, indicating there could be more than 4 million people with AS in China (J. Y. Jin, Zhonghua Nei Ke Za Zhi, vol. 49, pp. 832–835, 201; S. C. Ng, Seminars in Arthritis and Rheumatism, vol. 37, no. 1, pp. 39–47, 2007. )
·Korea 0.052% (Jin-Sung Park et al 2018)
·Taiwan 54,857 AS patients were documented  (Hsieh, M.-Y., & Kuo, C.-F. 2016)
Prevalence of Psoriatic Arthritis (PSA)
In Asia, Prevalence of Psoriasis
Prevalence of Ankylosing Spondylitis (AS)
·China is 0.02% (95% CI 0%, 0.07%) (Ru L et al 2011)
·Korea 14.1% of PsO (Hyo Jin Choi et al 2008)
·Taiwan 12.7% of PsO (Ting-Shun Wang et al 2016)
Better affordable medicines for patients in China and beyond.